COVID-19 Risk After Vaccination and Your Genetics

COVID-19 Risk After Vaccination: Breakthrough Susceptibility and Your Genetics

Vaccination against COVID-19 dramatically reduces the likelihood of severe illness, hospitalization, and death for virtually everyone. Yet a subset of vaccinated individuals still experience breakthrough infections — cases of COVID-19 that occur despite full vaccination. Emerging research indicates that inherited genetic variation plays a modest but measurable role in determining who among vaccinated people carries higher residual susceptibility to breakthrough infection. This trait — COVID-19 Risk After Vaccination — focuses specifically on that post-vaccination window, examining the biological pathways through which genetic differences may influence mucosal defenses, viral entry mechanisms, and immune signaling after the vaccine has already primed an adaptive response.

What is COVID-19 Risk After Vaccination?

COVID-19 Risk After Vaccination refers to the inherited component of an individual's susceptibility to contracting SARS-CoV-2 despite having received a COVID-19 vaccine. This is distinct from two related traits covered elsewhere on ExomeDNA: overall COVID-19 Infection Risk (susceptibility in an unvaccinated state) and COVID-19 Severity (how serious an infection becomes once established). Here, the focus is specifically on breakthrough infection — the probability of testing positive for SARS-CoV-2 after vaccination has been completed.

Breakthrough infections are common enough that they have become a major area of epidemiological and genetic study. Factors such as variant emergence, waning antibody titers, and immune senescence all contribute at the population level, but individual genetic architecture adds an additional layer of variation. Genetic factors relevant to this trait operate primarily through two broad mechanisms: mucosal barrier integrity at airway entry points, and innate and adaptive immune signaling that shapes how effectively a vaccinated immune system neutralizes viral exposure before infection is established.

It is important to state clearly: the genetic factors examined here represent a relatively modest component of post-vaccination susceptibility. Vaccination remains the single most effective intervention for reducing COVID-19 risk. The genetic profile discussed on this page does not override that benefit — it contextualizes the residual variation that persists even after vaccination.

The genetics behind COVID-19 Risk After Vaccination

Genome-wide association research has identified several loci with plausible biological roles in post-vaccination breakthrough susceptibility. The genes authorized for discussion in this trait — drawn from recent large-scale GWAS of vaccinated cohorts — cluster around two biological themes: mucosal surface glycobiology and immune regulatory signaling.

SLC6A20 is one of the most biologically compelling COVID-19 susceptibility loci to emerge from the pandemic genomics literature. This gene encodes a sodium-imino acid transporter that colocalizes with ACE2, the primary cell-surface receptor through which SARS-CoV-2 enters human cells. SLC6A20 is thought to modulate ACE2 expression and activity at epithelial surfaces, meaning that variants in this gene may subtly alter how accessible the viral entry receptor is at airway mucosa — a mechanism that could influence breakthrough susceptibility as well as unvaccinated infection risk.

FUT2 encodes fucosyltransferase 2, the enzyme responsible for secretor status — a well-characterized human phenotype determined by whether the H antigen is expressed on mucosal secretions. Non-secretors, who carry loss-of-function variants in FUT2, have altered glycan composition on airway mucus surfaces. Secretor status has long been associated with differential susceptibility to multiple respiratory and gastrointestinal viruses. In the context of SARS-CoV-2, FUT2 variants may influence how efficiently the virus binds at mucosal entry points, with implications for whether viral exposure after vaccination leads to a silent cleared infection or an established breakthrough case.

FUT6 encodes fucosyltransferase 6, a related enzyme that adds fucose to N-acetyllactosamine structures on cell surface and secreted glycoproteins. FUT6 is expressed in the liver and other tissues and contributes to the overall glycan landscape that shapes viral-host interactions at epithelial surfaces.

MUC16 (the protein better known clinically as CA-125) and MUC4 encode two large mucin glycoproteins that form the structural backbone of the protective mucus layer on airway epithelia. This mucus layer acts as the first physical barrier against inhaled pathogens. Variants affecting mucin protein structure, glycosylation, or expression level may alter barrier efficiency — potentially influencing whether a vaccinated airway mucosa can trap and clear viral particles before they reach susceptible epithelial cells.

NFKBIZ encodes an inhibitory regulator of NF-κB signaling, one of the central transcription factor pathways governing inflammatory and antiviral responses during acute infection. Variation in NFKBIZ may affect the speed and magnitude of the innate immune response at the moment of viral exposure — a window during which the vaccine-primed adaptive immune response is being recalled.

ST6GAL1 encodes a sialyltransferase that adds alpha-2,6-linked sialic acid residues to cell-surface and secreted glycoproteins. This modification affects cell surface composition in ways relevant to how viruses and immune cells interact with epithelial surfaces.

APOC1 encodes apolipoprotein C1, primarily known for its roles in lipid metabolism through modulation of lipoprotein lipase activity, but also implicated in immune modulation pathways. Its appearance in COVID-19 GWAS signals reflects the increasingly recognized crosstalk between lipid biology and antiviral immunity.

MXI1 is a transcriptional repressor in the MYC network with roles in cellular stress responses; its presence in COVID-19 genomic signals adds to evidence of broad transcriptional regulation in infection susceptibility. NXPE3 encodes a neuropathy target esterase-related protein whose precise mechanistic role in COVID-19 susceptibility is still under active investigation.

What the research says

Research base: Moderate.

The primary evidentiary foundation for this trait is a 2024 genome-wide association study published in Nature Communications by Alcalde-Herraiz and colleagues, which examined both vaccine seroconversion outcomes and breakthrough infection in the UK Biobank cohort — one of the largest and most deeply phenotyped biobank resources in the world [1]. This study is notable for explicitly studying vaccinated individuals, making it directly relevant to post-vaccination susceptibility rather than general COVID-19 risk. It identified multiple loci with genome-wide or suggestive significance for breakthrough outcomes and contextualized their biological plausibility through pathway analysis.

For information on how ExomeDNA evaluates and integrates genetic research, visit our methodology page.

A 2024 genome-wide association study of UK Biobank participants found multiple genetic loci associated with COVID-19 breakthrough infection risk in vaccinated individuals, including variants near genes involved in mucosal glycobiology and ACE2 regulation. [1]

The same 2024 Nature Communications analysis identified FUT2 secretor-status loci among signals associated with post-vaccination COVID-19 outcomes, consistent with the established role of mucosal glycan composition in respiratory virus susceptibility. [1]

The broader literature on COVID-19 host genetics — spanning over a dozen major GWAS conducted since 2020 — consistently implicates the SLC6A20/ACE2 locus, mucosal barrier genes including mucins and fucosyltransferases, and immune regulatory loci in COVID-19 susceptibility phenotypes. The extension of these findings specifically to the post-vaccination context represents an emerging and active research area. Effect sizes at individual loci are generally modest; no single gene variant confers dramatically elevated breakthrough risk. The genetic architecture of breakthrough susceptibility is polygenic, and environmental and behavioral factors — including the specific vaccine received, number of doses, time since last dose, and variant exposure — likely dwarf the genetic contribution at the population level.

Related traits on ExomeDNA that draw on overlapping but distinct evidence bases include COVID-19 Severity Genetic Risk and COVID-19 Infection Genetic Risk, which cover different outcome dimensions of SARS-CoV-2 biology.

How COVID-19 Risk After Vaccination affects you

For someone with a higher polygenic score on this trait, the practical implication is a modestly elevated probability of breakthrough infection relative to others who are similarly vaccinated. This does not mean vaccination is less beneficial — to the contrary, the genetic factors discussed here represent variation within the vaccinated population, not a comparison between vaccinated and unvaccinated states. Even individuals with higher genetic scores in this trait receive very substantial protection from vaccination against severe COVID-19 outcomes.

The mechanisms through which genetics influence breakthrough susceptibility are largely upstream of the adaptive immune response that vaccination trains. Mucosal barrier genes like MUC4, MUC16, FUT2, and FUT6 affect whether viral particles are physically trapped and cleared at airway surfaces before reaching epithelial cells that could become infected. ACE2-regulatory genes like SLC6A20 affect how accessible the viral entry receptor is. Immune signaling regulators like NFKBIZ affect the speed of innate responses. These mechanisms operate in parallel with — and largely independently of — the neutralizing antibody and T-cell responses that vaccines generate.

For individuals with higher scores, the most actionable responses focus on maintaining the conditions under which vaccine-primed immunity performs optimally: staying current with updated booster doses as recommended, supporting general immune health through adequate sleep, physical activity, and nutritional sufficiency, and being attentive to respiratory precautions in high-transmission settings. These behavioral factors influence the environmental side of the equation in ways that genetics cannot.

A higher genetic score on this trait may also be relevant context when discussing with a clinician whether additional precautions are warranted — for example, for individuals who are also immunocompromised or who have conditions that make even mild breakthrough infections consequential.

Working with your COVID-19 Risk After Vaccination profile

Understanding a higher score on this trait is most useful as motivation to optimize the factors that are within your control — not as a reason to view vaccination with skepticism. The research that identified these genetic signals was conducted exclusively in vaccinated cohorts; the genetic loci discussed here describe variation among people who were vaccinated, not an argument against vaccination.

Practical steps worth considering in consultation with a healthcare provider include keeping vaccination status current with updated formulations as they become available, discussing whether prophylactic antiviral medications (where clinically appropriate) represent an additional precaution during high-transmission periods, and attending to general respiratory health including air quality, sleep, and any underlying conditions that may affect mucosal immunity.

It is also worth recognizing that mucosal barrier function — the biological theme most central to several of the genes in this trait — is influenced by modifiable factors including hydration status, humidity in living environments, and smoking or vaping (which directly damages airway epithelial integrity and mucus function). These environmental interactions mean that the genetic predisposition here is not deterministic.

Individuals with a family history of COVID-19 complications, or those who are caring for immunocompromised household members, may find this profile particularly useful as part of a broader conversation with their clinician about layered protection strategies. See also our discussion of Immune and Inflammatory Risk Genetics for related context.

Related traits and genes

COVID-19 Risk After Vaccination sits within the Health & Longevity / Immune Response category on ExomeDNA and shares biological territory with several neighboring traits. The mucin and fucosyltransferase genes (MUC4, MUC16, FUT2, FUT6) that appear in this trait also have relevance to respiratory mucosal function more broadly, including in non-COVID respiratory conditions.

Within the same category, COVID-19 Severity Genetic Risk examines genetic factors affecting how serious a COVID-19 infection becomes once established — a distinct outcome from breakthrough susceptibility. COVID-19 Infection Genetic Risk covers susceptibility in the general (not specifically post-vaccination) context. Immune and Inflammatory Risk Genetics provides a broader view of inherited immune regulation that encompasses many of the same NF-κB and cytokine signaling pathways.

Cross-category connections are also meaningful here. The mucosal and glycan biology central to FUT2, MUC4, and ST6GAL1 overlaps with mechanisms relevant to Autoimmune Disease Risk, since mucosal immune tolerance and pathogen defense share many of the same molecular components. Respiratory Function Genetics covers the structural and functional determinants of lung capacity and airway architecture that provide the anatomical context within which these mucosal mechanisms operate.

Key genes in this trait include SLC6A20 (ACE2 colocalization and entry receptor modulation), FUT2 (secretor status and mucosal glycan composition), MUC16 and MUC4 (airway mucus barrier structural proteins), NFKBIZ (NF-κB immune regulatory signaling), ST6GAL1 (cell surface sialylation), FUT6 (fucosylation of cell surface glycans), and APOC1 (lipid-immune crosstalk).

Frequently asked questions

Does a higher score on this trait mean the COVID-19 vaccine will not work for me?
No. The genetic factors in this trait describe variation in residual breakthrough susceptibility among vaccinated people — not differences in how well the vaccine trains the immune system. Vaccination substantially reduces COVID-19 severity risk for everyone, including those with higher scores on this trait. A higher score means modestly elevated risk of breakthrough infection, not that vaccination is ineffective.

What does FUT2 secretor status have to do with COVID-19?
FUT2 determines whether certain blood group antigens are expressed on mucosal secretions — a trait known as secretor status. Non-secretors have altered glycan composition in their airway mucus, which affects how viruses interact with mucosal surfaces. Secretor status has been linked to susceptibility differences for multiple respiratory and gastrointestinal viruses, and variants in FUT2 have emerged in COVID-19 genomic analyses, plausibly through this mucosal mechanism.

Why does SLC6A20 appear in a COVID-19 genetics trait?
SLC6A20 encodes a transporter protein that physically colocalizes with ACE2 — the cell surface receptor SARS-CoV-2 uses to enter human cells. Variants in SLC6A20 may influence ACE2 expression or accessibility at airway epithelial surfaces, making it a plausible contributor to both initial infection susceptibility and, by extension, the residual susceptibility that persists after vaccination.

Is this trait the same as COVID-19 Severity?
No. COVID-19 Severity covers genetic factors that influence how serious an infection becomes once established — including risk of hospitalization or severe respiratory complications. This trait focuses on the earlier step: whether a vaccinated person contracts COVID-19 at all (breakthrough infection). The two traits share some biological themes but represent distinct phenotypes with partly distinct genetic architectures.

How reliable is this genetic information?
The research base for this trait is rated Moderate. The primary evidence comes from a large, well-conducted 2024 genome-wide association study in the UK Biobank using vaccinated participants. The biological mechanisms for several key genes (especially SLC6A20 and FUT2) are well-supported by converging evidence. However, the specific genetic architecture of post-vaccination breakthrough susceptibility is still an active research area, effect sizes at individual loci are modest, and replication across diverse ancestries is ongoing. ExomeDNA will update trait scores as stronger evidence accumulates.

Can anything be done to reduce breakthrough infection risk?
Several modifiable factors intersect with the biological mechanisms in this trait. Staying current with updated vaccine formulations, avoiding smoking or vaping (which impairs airway mucosal integrity), maintaining good sleep and general immune health, and discussing additional precautions with a clinician during high-transmission periods are all reasonable steps. None of these eliminate genetic predisposition, but the genetic contribution to breakthrough risk is one component among many that includes behavioral and environmental factors that are more directly modifiable.